Scroll

trifluoperazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2740	117-89-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: trifluoperazine trifluoperazin trifluoromethylperazine trifluoroperazine trifluperazine triflurin triperazine trifluoperazine hydrochloride trifluoperazine dihydrochloride trifluoperazine HCl flupazine	A phenothiazine with actions similar to CHLORPROMAZINE. It is used as an antipsychotic and an antiemetic. Molecular weight: 407.50 Formula: C21H24F3N3S CLOGP: 4.89 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 9.72 ALOGS: -4.67 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

trifluoperazine
trifluoperazin
trifluoromethylperazine
trifluoroperazine
trifluperazine
triflurin
triperazine
trifluoperazine hydrochloride
trifluoperazine dihydrochloride
trifluoperazine HCl
flupazine

A phenothiazine with actions similar to CHLORPROMAZINE. It is used as an antipsychotic and an antiemetic.

Molecular weight: 407.50
Formula: C21H24F3N3S
CLOGP: 4.89
LIPINSKI: 0
HAC: 3
HDO: 0
TPSA: 9.72
ALOGS: -4.67
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O
8	mg	P
20	mg	R

ADMET properties:

Show entries

Search:

Property	Value	Reference
S (Water solubility)	50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 2 of 2 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
April 16, 1959	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	69.33	49.41	24	427	72494	63416077

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Antipsychotic drug level below therapeutic	495.87	225.69	88	1545	2459	34952839
Therapeutic product effect variable	479.03	225.69	85	1548	2371	34952927
Disinhibition	475.10	225.69	88	1545	3138	34952160
Obsessive-compulsive disorder	450.85	225.69	92	1541	5472	34949826
Euphoric mood	431.90	225.69	89	1544	5552	34949746
Increased appetite	401.88	225.69	88	1545	7341	34947957
Akathisia	394.20	225.69	88	1545	8021	34947277
Suicide attempt	280.89	225.69	94	1539	39022	34916276

Showing 1 to 8 of 8 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Antipsychotic drug level below therapeutic	157.59	62.82	25	1072	1213	79742078
Therapeutic product effect variable	145.50	62.82	25	1072	1984	79741307
Disinhibition	139.08	62.82	25	1072	2573	79740718
Obsessive-compulsive disorder	124.28	62.82	26	1071	5901	79737390
Euphoric mood	122.95	62.82	27	1070	7699	79735592
Suicide attempt	107.73	62.82	41	1056	82891	79660400
Dyslipidaemia	101.73	62.82	25	1072	11608	79731683
Increased appetite	101.00	62.82	25	1072	11953	79731338
Akathisia	98.48	62.82	25	1072	13234	79730057
Obesity	74.42	62.82	25	1072	35100	79708191

Showing 1 to 10 of 11 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N05AB06	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure
CHEBI has role	CHEBI:37930	phenothiazine antipsychotic drugs
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:77402	EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors
CHEBI has role	CHEBI:86385	Delta(7)-cholestenol Delta(7)-Delta(8)-isomerase inhibitors
FDA CS	M0016525	Phenothiazines
FDA EPC	N0000175746	Phenothiazine
MeSH PA	D000932	Antiemetics
MeSH PA	D014150	Antipsychotic Agents

Showing 1 to 10 of 19 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Anxiety	indication	48694002
Schizophrenia	indication	58214004	DOID:5419
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Cirrhosis of liver	contraindication	19943007	DOID:5082
Glaucoma	contraindication	23986001	DOID:1686
Orthostatic hypotension	contraindication	28651003
Retinal disorder	contraindication	29555009	DOID:5679
Alcoholic liver damage	contraindication	41309000
Low blood pressure	contraindication	45007003

Showing 1 to 10 of 24 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.74	Basic
pKa2	4.74	Basic
pKa3	2.72	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.84	PDSP	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.19	PDSP
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.82	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.29	DRUG MATRIX
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Enzyme	Q15125	EBP_HUMAN		Ki	8.10	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Ki	5.19	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.02	PDSP
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	7.90	IUPHAR
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	ANTAGONIST	Ki	6.40	IUPHAR
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.85	PDSP

Showing 1 to 10 of 35 entries

Previous1 2 3 4Next

External reference:

Show entries

Search:

ID	Source
001481	NDDF
004590	NDDF
10800	RXNORM
214	IUPHAR_LIGAND_ID
214IZI85K3	UNII
2926	MMSL
373524005	SNOMEDCT_US
4018843	VANDF
4019957	VUID
4019957	VANDF

Showing 1 to 10 of 27 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TRIFLUOPERAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-305	TABLET, FILM COATED	2 mg	ORAL	ANDA	11 sections
Trifluoperazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2401	TABLET, FILM COATED	1 mg	ORAL	ANDA	16 sections
Trifluoperazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2402	TABLET, FILM COATED	2 mg	ORAL	ANDA	16 sections
Trifluoperazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2405	TABLET, FILM COATED	5 mg	ORAL	ANDA	16 sections
Trifluoperazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2410	TABLET, FILM COATED	10 mg	ORAL	ANDA	16 sections
Trifluoperazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8028	TABLET, FILM COATED	1 mg	ORAL	ANDA	15 sections
Trifluoperazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8028	TABLET, FILM COATED	1 mg	ORAL	ANDA	15 sections
Trifluoperazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8032	TABLET, FILM COATED	2 mg	ORAL	ANDA	15 sections
Trifluoperazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8032	TABLET, FILM COATED	2 mg	ORAL	ANDA	15 sections
Trifluoperazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8034	TABLET, FILM COATED	5 mg	ORAL	ANDA	15 sections

Showing 1 to 10 of 29 entries

Previous1 2 3Next